Plain-English translation of NCT07164313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is the first human trial of , a new medication that targets and attacks cancer cells in people with advanced solid tumors, particularly hepatocellular carcinoma (liver cancer), squamous cell lung cancer, and germ cell tumors. The trial has two parts: first, researchers will carefully increase doses to find the safest amount, and second, they will test whether the medication can slow or shrink tumors at the recommended dose.
Current treatments for these advanced cancers have limited effectiveness, and many patients need new options. This medication uses a novel approach—an antibody that targets a specific protein on cancer cells—to potentially offer a better treatment choice.
You likely qualify if…
You likely don't qualify if…
You will receive doses of the medication, likely by infusion at a hospital or clinic. The trial is divided into phases: in the first phase, doses will be slowly increased while doctors carefully monitor your health and any side effects; in the second phase, the medication will be given at the dose found to be safe and potentially effective. You will have regular blood tests, imaging scans, and check-in visits to see how you are responding and to watch for any adverse effects. The exact duration and visit schedule will depend on which part of the trial you join and how your body responds to the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States